Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme

Journal of Neuro-Oncology

Volumn 121, Issue 2, 2015, Pages 319-329

  Hunn, Martin K ^a,b,c   Bauer, Evelyn ^a   Wood, Catherine E ^a,c   Gasser, Olivier ^a   Dzhelali, Marina ^c   Ancelet, Lindsay R ^a   Mester, Brigitta ^a   Sharples, Katrina J ^d,e   Findlay, Michael P ^d   Hamilton, David A ^c   Hermans, Ian F ^a,b  

^a MALAGHAN INSTITUTE OF MEDICAL RESEARCH   (New Zealand)

^b VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

^c CAPITAL AND COAST DISTRICT HEALTH BOARD   (New Zealand)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

^e UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Chemoresistance; Combination therapy; Dendritic cell based vaccination; Glioblastoma multiforme; T cells; Temozolomide

Indexed keywords

DENDRITIC CELL VACCINE; GAMMA INTERFERON; TEMOZOLOMIDE; ALKYLATING AGENT; CANCER VACCINE; DACARBAZINE;

ADJUVANT THERAPY; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURGERY; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DENDRITIC CELL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERANCE; ENZYME LINKED IMMUNOSPOT ASSAY; FEASIBILITY STUDY; FEMALE; GLIOBLASTOMA; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VIVO STUDY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RADIATION NECROSIS; RECURRENT DISEASE; RETREATMENT; THERAPY DELAY; THROMBOCYTOPENIA; VACCINATION; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; BRAIN; BRAIN NEOPLASMS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; IMMUNOLOGY; MULTIMODALITY CANCER THERAPY; NEOPLASM RECURRENCE, LOCAL; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN; BRAIN NEOPLASMS; CANCER VACCINES; COMBINED MODALITY THERAPY; DACARBAZINE; DENDRITIC CELLS; DISEASE-FREE SURVIVAL; FEASIBILITY STUDIES; FEMALE; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETREATMENT; TREATMENT OUTCOME;

EID: 84925543609     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-014-1635-7     Document Type: Article

References (43)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996. doi:10.1056/NEJMoa043330
2. Chen C, Xu T, Lu Y, Chen J, Wu S (2013) The efficacy of temozolomide for recurrent glioblastoma multiforme. Eur J Neurol 20(2):223–230. doi:10.1111/j.1468-1331.2012.03778.x
3. Perry JR, Bélanger K, Mason WP, Fulton D, Kavan P, Easaw J, Shields C, Kirby S, Macdonald DR, Eisenstat DD, Thiessen B, Forsyth P, Pouliot J-F (2010) Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol 28(12):2051–2057. doi:10.1200/JCO.2009.26.5520
4. Franceschi E, Omuro AMP, Lassman AB, Demopoulos A, Nolan C, Abrey LE (2005) Salvage temozolomide for prior temozolomide responders. Cancer 104(11):2473–2476. doi:10.1002/cncr.21564
5. Wick A, Pascher C, Wick W, Jauch T, Weller M, Bogdahn U, Hau P (2009) Rechallenge with temozolomide in patients with recurrent gliomas. J Neurol 256(5):734–741. doi:10.1007/s00415-009-5006-9
6. Vauleon E, Avril T, Collet B, Mosser J, Quillien V (2010) Overview of cellular immunotherapy for patients with glioblastoma. Clin Dev Immunol 2010:1–18. doi:10.1155/2010/689171
7. Xu X, Stockhammer F, Schmitt M (2012) Cellular-based immunotherapies for patients with glioblastoma multiforme. Clin Dev Immunol 2012:764213. doi:10.1155/2012/764213
8. Wheeler CJ, Das A, Liu G, Yu JS, Black KL (2004) Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res 10(16):5316–5326. doi:10.1158/1078-0432.CCR-04-0497
9. Ramakrishnan R, Antonia S, Gabrilovich DI (2008) Combined modality immunotherapy and chemotherapy: a new perspective. Cancer Immunol Immunother 57(10):1523–1529. doi:10.1007/s00262-008-0531-4
10. Natsume A, Ishii D, Wakabayashi T, Tsuno T, Hatano H, Mizuno M, Yoshida J (2005) IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Cancer Res 65(17):7573–7579. doi:10.1158/0008-5472.CAN-05-0036
11. Radfar S, Wang Y, Khong HT (2009) Activated CD4 + T cells dramatically enhance chemotherapeutic tumor responses in vitro and in vivo. J Immunol 183(10):6800–6807. doi:10.4049/jimmunol.0901747
12. Liu G, Khong HT, Wheeler CJ, Yu JS, Black KL, Ying H (2003) Molecular and functional analysis of tyrosinase-related protein (TRP)-2 as a cytotoxic T lymphocyte target in patients with malignant glioma. J Immunother 26(4):301–312
13. Chi DD, Merchant RE, Rand R, Conrad AJ, Garrison D, Turner R, Morton DL, Hoon DS (1997) Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am J Pathol 150(6):2143–2152
14. Chu W, Pak BJ, Bani MR, Kapoor M, Lu SJ, Tamir A, Kerbel RS, Ben-David Y (2000) Tyrosinase-related protein 2 as a mediator of melanoma specific resistance to cis-diamminedichloroplatinum(II): therapeutic implications. Oncogene 19(3):395–402. doi:10.1038/sj.onc.1203315
15. Pak BJ, Chu W, Lu SJ, Kerbel RS, Ben-David Y (2001) Lineage-specific mechanism of drug and radiation resistance in melanoma mediated by tyrosinase-related protein 2. Cancer Metastasis Rev 20(1–2):27–32
16. Nishioka E, Funasaka Y, Kondoh H, Chakraborty AK, Mishima Y, Ichihashi M (1999) Expression of tyrosinase, TRP-1 and TRP-2 in ultraviolet-irradiated human melanomas and melanocytes: TRP-2 protects melanoma cells from ultraviolet B induced apoptosis. Melanoma Res 9(5):433–443
17. Liu G, Akasaki Y, Khong HT, Wheeler CJ, Das A, Black KL, Yu JS (2005) Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy. Oncogene 24(33):5226–5234. doi:10.1038/sj.onc.1208519
18. Chakravarti A, Noll E, Black PM, Finkelstein DF, Finkelstein DM, Dyson NJ, Loeffler JS (2002) Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol 20(4):1063–1068
19. Preusser M, Gelpi E, Matej R, Marosi C, Dieckmann K, Rössler K, Budka H, Hainfellner JA (2005) No prognostic impact of survivin expression in glioblastoma. Acta Neuropathol 109(5):534–538. doi:10.1007/s00401-005-0992-x
20. Ciesielski MJ, Ahluwalia MS, Munich SA, Orton M, Barone T, Chanan-Khan A, Fenstermaker RA (2010) Antitumor cytotoxic T-cell response induced by a survivin peptide mimic. Cancer Immunol Immunother 59(8):1211–1221. doi:10.1007/s00262-010-0845-x
21. Choi BD, Archer GE, Mitchell DA, Heimberger AB, Mclendon RE, Bigner DD, Sampson JH (2009) EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathol 19(4):713–723. doi:10.1111/j.1750-3639.2009.00318.x
22. Romani N, Reider D, Heuer M, Ebner S, Kämpgen E, Eibl B, Niederwieser D, Schuler G (1996) Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods 196(2):137–151
23. O’Rourke MGE, Johnson M, Lanagan C, See J, Yang J, Bell JR, Slater GJ, Kerr BM, Crowe B, Purdie DM, Elliott SL, Ellem KAO, Schmidt CW (2003) Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol Immunother 52(6):387–395. doi:10.1007/s00262-003-0375-x
24. Shah GD, Kesari S, Xu R, Batchelor TT, O’Neill AM, Hochberg FH, Levy B, Bradshaw J, Wen PY (2006) Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas. Neuro-Oncology 8(1):38–46. doi:10.1215/S1522851705000529
25. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47(1):207–214
26. Bartholomae WC, Rininsland FH, Eisenberg JC, Boehm BO, Lehmann PV, Tary-Lehmann M (2004) T cell immunity induced by live, necrotic, and apoptotic tumor cells. J Immunol 173(2):1012–1022
27. Chamberlain MC, Glantz MJ, Chalmers L, Van Horn A, Sloan AE (2007) Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 82(1):81–83. doi:10.1007/s11060-006-9241-y
28. Kimura T, McKolanis JR, Dzubinski LA, Islam K, Potter DM, Salazar AM, Schoen RE, Finn OJ (2013) MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. Cancer Prev Res (Phila) 6(1):18–26. doi:10.1158/1940-6207.CAPR-12-0275
29. Bauer M, Goldstein M, Heylmann D, Kaina B (2012) Human monocytes undergo excessive apoptosis following temozolomide activating the ATM/ATR pathway while dendritic cells and macrophages are resistant. PLoS One 7(6):e39956. doi:10.1371/journal.pone.0039956
30. Schmidt M, Pauels HG, Lügering N, Lügering A, Domschke W, Kucharzik T (1999) Glucocorticoids induce apoptosis in human monocytes: potential role of IL-1 beta. J Immunol 163(6):3484–3490
31. Ogden AT, Horgan D, Waziri A, Anderson D, Louca J, Mckhann GM, Sisti MB, Parsa AT, Bruce JN (2006) Defective receptor expression and dendritic cell differentiation of monocytes in glioblastomas. Neurosurgery 59(4):902–910. doi:10.1227/01.NEU.0000233907.03070.7B
32. Curran WJ, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE (1993) Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials. J Natl Cancer Inst 85(9):704–710
33. Paravati AJ, Heron DE, Landsittel D, Flickinger JC, Mintz A, Chen Y-F, Huq MS (2011) Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of radiation therapy oncology group-recursive partitioning analysis in the IMRT and temozolomide era. J Neurooncol 104(1):339–349. doi:10.1007/s11060-010-0499-8
34. De Vleeschouwer S, Ardon H, Van Calenbergh F, Sciot R, Wilms G, Van Loon J, Goffin J, Van Gool S (2012) Stratification according to HGG-IMMUNO RPA model predicts outcome in a large group of patients with relapsed malignant glioma treated by adjuvant postoperative dendritic cell vaccination. Cancer Immunol Immunother 61(11):2105–2112. doi:10.1007/s00262-012-1271-z
35. Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ, Lin J-W, Chute DJ, Mischel PS, Cloughesy TF, Roth MD (2005) Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 11(15):5515–5525. doi:10.1158/1078-0432.CCR-05-0464
36. Sampson JH, Aldape KD, Archer GE, Coan A, Desjardins A, Friedman AH, Friedman HS, Gilbert MR, Herndon JE, Mclendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling R, Shi W, Vredenburgh JJ, Bigner DD, Heimberger AB (2011) Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro-Oncology 13(3):324–333. doi:10.1093/neuonc/noq157
37. Kim C-H, Woo S-J, Park J-S, Kim H-S, Park M-Y, Park S-D, Hong Y-K, Kim T-G (2007) Enhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma. Immunology 122(4):615–622. doi:10.1111/j.1365-2567.2007.02680.x
38. Gangemi RMR, Griffero F, Marubbi D, Perera M, Capra MC, Malatesta P, Ravetti GL, Zona GL, Daga A, Corte G (2009) SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells 27(1):40–48. doi:10.1634/stemcells.2008-0493
39. Yang Y-P, Chien Y, Chiou G-Y, Cherng J-Y, Wang M-L, Lo W-L, Chang Y-L, Huang P-I, Chen Y-W, Shih Y-H, Chen M-T, Chiou S-H (2012) Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI. Biomaterials 33(5):1462–1476. doi:10.1016/j.biomaterials.2011.10.071
40. Ardon H, Van Gool SW, Verschuere T, Maes W, Fieuws S, Sciot R, Wilms G, Demaerel P, Goffin J, Van Calenbergh F, Menten J, Clement P, Debiec-Rychter M, De Vleeschouwer S (2012) Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial. Cancer Immunol Immunother 61(11):2033–2044. doi:10.1007/s00262-012-1261-1
41. Prins RM, Wang X, Soto H, Young E, Lisiero DN, Fong B, Everson R, Yong WH, Lai A, Li G, Cloughesy TF, Liau LM (2013) Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients. J Immunother 36(2):152–157. doi:10.1097/CJI.0b013e3182811ae4
42. Phuphanich S, Wheeler CJ, Rudnick JD, Mazer M, Wang H, Nuño MA, Richardson JE, Fan X, Ji J, Chu RM, Bender JG, Hawkins ES, Patil CG, Black KL, Yu JS (2012) Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother. doi:10.1007/s00262-012-1319-0
43. Sabado RL, Bhardwaj N (2013) Dendritic cell immunotherapy. Ann N Y Acad Sci 1284:31–45. doi:10.1111/nyas.12125